Phase III clinical trials has been released for its multiple scleroses drug ocrelizumab, for use in relapsing forms of the disease or in cases of primary progressive multiple sclerosis (PPMS)—and the results appear to be very promising.
Ocrelizumab is a recombinant humanized monoclonal antibody against immune B cells that express CD20 proteins at their surface. These cells are thought to be a key contributor to the myelin and neuron damage that leads to motor function impairment, irreversible neurological disability and paralysis in MS patients. “B cells can contribute to the pathophysiology of MS,” explained Dr. Hauser during his presentation, “targeting CD20-B cells may preserve B cell reconstitution and long-term immune memory.”
85% of patients with MS experience relapse, wit...
Read More
Recent Comments